Genmab A/S (OTCMKTS:GNMSF – Get Free Report) saw unusually-strong trading volume on Wednesday. Approximately 20,786 shares were traded during trading, an increase of 712% from the average daily volume of 2,559 shares. The stock last traded at $575.00 and had previously closed at $439.05.
Genmab A/S Price Performance
The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $35.37 billion, a price-to-earnings ratio of 45.06 and a beta of 0.75. The stock’s 50 day moving average price is $365.68 and its two-hundred day moving average price is $303.90.
About Genmab A/S
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Featured Stories
- Five stocks we like better than Genmab A/S
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
